Actively Recruiting
DAOIB for the Treatment of Cognitive Impairment Induced by COVID-19 - An Open Trial
Led by Chang Gung Memorial Hospital · Updated on 2026-03-19
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate DAOIB as a treatment for cognitive impairments in patients with long COVID. The trial is open-label and will last 24 weeks. It focuses on assessing changes in cognitive function, mood, overall functioning, and quality of life in adults experiencing brain fog after COVID-19 infection. Participants will receive DAOIB continuously for 24 weeks, with the dose adjusted every 8 weeks based on clinical evaluation. The treatment period includes assessments at weeks 0, 8, 16, and 24. There is no placebo or comparator group in this open trial. During the study, patients will be evaluated every 8 weeks using various scales including the Alzheimer's disease assessment scale for cognition, mood and anxiety rating scales, quality of life questionnaires, and other cognitive tests. Researchers will monitor changes from baseline at each visit to understand the effects of DAOIB on long COVID cognitive symptoms.
CONDITIONS
Brief Title
DAOIB for the Treatment of Brain Fog
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 100 years
- Diagnosed with post-COVID-19 condition as defined by WHO with symptoms lasting at least 2 months and cognitive impairments caused by COVID-19
- Physically healthy with all laboratory tests (urine, blood, biochemical, electrocardiograph) within normal limits
- Have sufficient education to communicate effectively and able to complete study assessments
You will not qualify if you...
- History of significant cerebrovascular disease
- Hachinski Ischemic Score greater than 4
- Major neurological, psychiatric, or medical conditions other than long COVID cognitive impairments
- Use of memantine (an NMDAR partial antagonist)
- Substance abuse or dependence, including alcohol
- Symptoms of delusion, hallucination, or delirium
- Severe visual or hearing loss
- Inability to follow the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive DAOIB, with the dose adjusted every 8 weeks based on clinical evaluation.
Visits at baseline and every 8 weeks during treatment (total 4 visits)
Trial Site Locations
Total: 1 location
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 886
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here